Targeting NF-κB and induction of apoptosis by novel NF-κB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells

Noriko Kimura, Yoshitaka Miyakawa, Kanoko Kohmura, Kazuo Umezawa, Yasuo Ikeda, Masahiro Kizaki

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

A new NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), inhibited proliferation and induced apoptosis in human Burkitt lymphoma, HS-Sultan and Daudi cell lines. The activation of caspase-3 and the cleavage of caspase substrate PARP were observed after treatment with DHMEQ. The induction of apoptosis by DHMEQ was prevented by the pretreatment of Burkitt lymphoma cells with pan-caspase inhibitor, z-VAD-FMK. The expression of anti-apoptotic factors such as IAP-1 and XIAP was suppressed by DHMEQ. Phosphorylation of ERK and JNK was induced by DHMEQ. In conclusion, these results demonstrate that NF-κB might be an ideal target to develop for new anti-cancer drugs for Burkitt lymphoma.

Original languageEnglish
Pages (from-to)1529-1535
Number of pages7
JournalLeukemia Research
Volume31
Issue number11
DOIs
Publication statusPublished - 2007 Nov

Fingerprint

Burkitt Lymphoma
Apoptosis
Caspase Inhibitors
Caspases
Caspase 3
Phosphorylation
dehydroxymethylepoxyquinomicin
Cell Line
Pharmaceutical Preparations
Neoplasms

Keywords

  • Apoptosis
  • Burkitt lymphoma
  • Caspase-3
  • IAP
  • NF-κB

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Targeting NF-κB and induction of apoptosis by novel NF-κB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells. / Kimura, Noriko; Miyakawa, Yoshitaka; Kohmura, Kanoko; Umezawa, Kazuo; Ikeda, Yasuo; Kizaki, Masahiro.

In: Leukemia Research, Vol. 31, No. 11, 11.2007, p. 1529-1535.

Research output: Contribution to journalArticle

Kimura, Noriko ; Miyakawa, Yoshitaka ; Kohmura, Kanoko ; Umezawa, Kazuo ; Ikeda, Yasuo ; Kizaki, Masahiro. / Targeting NF-κB and induction of apoptosis by novel NF-κB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells. In: Leukemia Research. 2007 ; Vol. 31, No. 11. pp. 1529-1535.
@article{79dfb20892cd4f8bb272d291314d462a,
title = "Targeting NF-κB and induction of apoptosis by novel NF-κB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells",
abstract = "A new NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), inhibited proliferation and induced apoptosis in human Burkitt lymphoma, HS-Sultan and Daudi cell lines. The activation of caspase-3 and the cleavage of caspase substrate PARP were observed after treatment with DHMEQ. The induction of apoptosis by DHMEQ was prevented by the pretreatment of Burkitt lymphoma cells with pan-caspase inhibitor, z-VAD-FMK. The expression of anti-apoptotic factors such as IAP-1 and XIAP was suppressed by DHMEQ. Phosphorylation of ERK and JNK was induced by DHMEQ. In conclusion, these results demonstrate that NF-κB might be an ideal target to develop for new anti-cancer drugs for Burkitt lymphoma.",
keywords = "Apoptosis, Burkitt lymphoma, Caspase-3, IAP, NF-κB",
author = "Noriko Kimura and Yoshitaka Miyakawa and Kanoko Kohmura and Kazuo Umezawa and Yasuo Ikeda and Masahiro Kizaki",
year = "2007",
month = "11",
doi = "10.1016/j.leukres.2007.02.015",
language = "English",
volume = "31",
pages = "1529--1535",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "11",

}

TY - JOUR

T1 - Targeting NF-κB and induction of apoptosis by novel NF-κB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells

AU - Kimura, Noriko

AU - Miyakawa, Yoshitaka

AU - Kohmura, Kanoko

AU - Umezawa, Kazuo

AU - Ikeda, Yasuo

AU - Kizaki, Masahiro

PY - 2007/11

Y1 - 2007/11

N2 - A new NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), inhibited proliferation and induced apoptosis in human Burkitt lymphoma, HS-Sultan and Daudi cell lines. The activation of caspase-3 and the cleavage of caspase substrate PARP were observed after treatment with DHMEQ. The induction of apoptosis by DHMEQ was prevented by the pretreatment of Burkitt lymphoma cells with pan-caspase inhibitor, z-VAD-FMK. The expression of anti-apoptotic factors such as IAP-1 and XIAP was suppressed by DHMEQ. Phosphorylation of ERK and JNK was induced by DHMEQ. In conclusion, these results demonstrate that NF-κB might be an ideal target to develop for new anti-cancer drugs for Burkitt lymphoma.

AB - A new NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), inhibited proliferation and induced apoptosis in human Burkitt lymphoma, HS-Sultan and Daudi cell lines. The activation of caspase-3 and the cleavage of caspase substrate PARP were observed after treatment with DHMEQ. The induction of apoptosis by DHMEQ was prevented by the pretreatment of Burkitt lymphoma cells with pan-caspase inhibitor, z-VAD-FMK. The expression of anti-apoptotic factors such as IAP-1 and XIAP was suppressed by DHMEQ. Phosphorylation of ERK and JNK was induced by DHMEQ. In conclusion, these results demonstrate that NF-κB might be an ideal target to develop for new anti-cancer drugs for Burkitt lymphoma.

KW - Apoptosis

KW - Burkitt lymphoma

KW - Caspase-3

KW - IAP

KW - NF-κB

UR - http://www.scopus.com/inward/record.url?scp=35448994812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35448994812&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2007.02.015

DO - 10.1016/j.leukres.2007.02.015

M3 - Article

C2 - 17466373

AN - SCOPUS:35448994812

VL - 31

SP - 1529

EP - 1535

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 11

ER -